Veuillez visiter la page anglaise pour plus de détails.
- CR1816MK Advanced, Recurrent or Metastatic Endometrial Cancer - Lenvatinib plus Pembrolizumab vs Physician’s choice (Doxorubicin or paclitaxel)
- CR1525MK Advance Solid Tumor Pembrolizumab
- CA209-484 Solid Tumors of High Tumor Mutational Burden (TMB-H) Nivolumab +/- Ipilimumab
- CAPTUR (Canadian Profiling and Targeted Agent Utilization Trial)